About this item:

57 Views | 23 Downloads

Author Notes:

Dr John E McGeary, john_mcgeary@brown.edu

JJ and JEM drafted the initial proposal, with input from NSP, RMS and LB. MJQ, JLC and CBB-B drafted the manuscript, which all authors reviewed and revised.

We thank research participants and our clinical collaborators at the Providence VA Medical Center for their ongoing support.

Disclosures: None declared

Subjects:

Research Funding:

This work was supported by the Center for Neurorestoration and Neurotechnology (N2864-C) and RR&D Small Projects in Rehabilitation Research (SPiRE; 5I21RX003338) from the US Department of Veterans Affairs, Rehabilitation Research and Development Service, Providence, Rhode Island, USA. Device support on this project is supported through clinical trial contracts between Wave Neuroscience and the Ocean State Research Institute and Veterans Affairs Providence.

Keywords:

  • Telemedicine
  • mental health
  • Substance misuse
  • Clinical trials

Synchronised transcranial magnetic stimulation for substance use-disordered Veterans: protocol for the pilot sham-controlled acceptability trial

Tools:

Journal Title:

BMJ Open

Volume:

Volume 13, Number 1

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

Substance use disorders (SUDs) take an enormous toll on US Veterans and civilians alike. Existing empirically supported interventions vary by substance and demonstrate only moderate efficacy. Non-invasive brain stimulation represents an innovative treatment for SUDs, yet aspects of traditional neurostimulation may hinder its implementation in SUD populations. Synchronised transcranial magnetic stimulation (sTMS) uses rotating rare earth magnets to deliver low-field stimulation synchronised to an individual’s alpha peak frequency that is safe for at-home administration. The current trial aims to assess the acceptability and feasibility of sTMS, as well as the safety of at-home sTMS administration for substance-disordered Veterans.

Copyright information:

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/).
Export to EndNote